Sanofi US News

- An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio -

- Health care providers anticipating initial shipments by early August to kick off influenza immunization season -

- Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio -

- Data presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) -

- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -

- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -

- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) -

- Kevzara is now available to U.S. patients -

-- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season --

Op-Ed by Olivier Brandicourt

- New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA -

- New action date for Kevzara U.S. BLA is May 22, 2017 -

- Monthly dosing schedule now approved in both United States and European Union -

- New U.S. indication approved for Thymoglobulin [anti-thymocyte globulin (rabbit)]; first since 1998 -

- New toothpaste introduced by the trusted leader in mouthwashes for more than 30 years helps motivate kids to brush their teeth -

- DELIVER 2 Data Showed Reduction in Hypoglycemic Events Related to Inpatient or Emergency Department Visits -

- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema -

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'

Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -

- Praluent continues to be available to patients in the U.S. -

- Antihistamine Offers 24-Hour Relief to Adults and Children with Seasonal and Year-Round Allergies -

Employee holiday drive echoes company’s holistic approach in supporting Monroe County Head Start and Pocono Alliance families

Data also Shows Men Consider Sexual Health to be an Important Priority

- In the MONARCH Study, Sarilumab Monotherapy Demonstrated Superiority Over Adalimumab Monotherapy in Adults with Active Rheumatoid Arthritis -

2016 could be the year of the last case of wild poliomyelitis worldwide

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

- Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress -

Funds will be used for phase II development and manufacturing

- Joshua Riff, M.D., Named Chief Executive Officer -

- Adlyxin™ is approved as Lyxumia® in more than 60 countries -

- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -

-- Findings reveal that some patients are frustrated and discontinued medication because they were not reaching their individualized A1C target quick enough --

Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.

- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -

- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

- Collaborations Will Work towards Predicting Medication Adherence -

- Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities -

Pre-clinical immunogenicity and efficacy data published in Journal of Virology

Praluent is now covered by most health insurance and Medicare plans

- FDA decision anticipated in August 2016 -

America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category

Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids

Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards

- Aims to advance animal health though internet-connected technology and networks -

Record-breaking holiday gift drive responds to increased homelessness rates

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- 74 percent of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal -

- Data Show Significant Improvement in Signs and Symptoms and Physical Function in Rheumatoid Arthritis Patients who were Inadequate Responders to or Intolerant of TNF-Alpha Inhibitors (TNF-IR) -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- Crucial vaccination with Raboral V-RG® continues to help protect wildlife and people against this fatal disease